Key takeaways
- TRIUMPH is Eli Lilly’s phase 3 programme for retatrutide in obesity: four registrational trials with more than 5,800 participants, all randomised, double-blind and placebo-controlled.
- TRIUMPH-1 and TRIUMPH-2 are basket trials: sub-studies in knee osteoarthritis and obstructive sleep apnoea sit inside the main weight trials.
- TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 were published in NEJM and The Lancet between 29 September and 8 November 2026; TRIUMPH-3, in 1,946 adults with cardiovascular disease, is completed, and we found no journal paper for it (PubMed, 18 Nov 2026).
- ClinicalTrials.gov lists TRIUMPH-5 to TRIUMPH-9 and TRIUMPH-Outcomes as active, with primary completion expected from November 2026 to February 2029.
- We describe design, not results: retatrutide is investigational and approved nowhere, and nothing in these trials describes products sold online.
01TRIUMPH trials at a glance
Every trial on ClinicalTrials.gov that carries the TRIUMPH name, plus the outcomes trial Lilly lists under it, checked on 18 November 2026. Numbers for published trials are the papers’; for the others, the registry’s estimates. Dates in the last column are expected primary completion.
| Trial and registry ID | Who took part, and the comparison | Length | Primary endpoint | Status and paper |
|---|---|---|---|---|
| TRIUMPH-1 · NCT05929066 | 2,339 adults with obesity, without diabetes, against placebo; sub-studies of 574 with knee osteoarthritis (TRIUMPH-1-OA) and 243 with obstructive sleep apnoea (TRIUMPH-1-OSA) | 80 weeks | Percentage change in body weight; in the sub-studies, a knee-pain score (WOMAC) and the apnoea–hypopnoea index | Completed. NEJM, online 29 Sep 2026; sub-studies in NEJM, 21 Oct and 8 Nov 2026 |
| TRIUMPH-2 · NCT05929079 | 1,152 adults with type 2 diabetes and a body-mass index (BMI) of 27 or more, at 92 centres in eight countries, against placebo; sleep apnoea sub-study of 448 (TRIUMPH-2-OSA) | 80 weeks | Percentage change in body weight; apnoea–hypopnoea index in the sub-study | Completed. The Lancet, online 29 Sep 2026; sub-study in NEJM, 21 Oct 2026 |
| TRIUMPH-3 · NCT05882045 | 1,946 adults with severe obesity and established cardiovascular disease, as the registry describes them, against placebo | 80 weeks | Percentage change in body weight | Completed (primary completion Apr 2026). No journal paper found (PubMed, 18 Nov 2026) |
| TRIUMPH-4 · NCT05931367 | 445 adults without diabetes, with painful knee osteoarthritis and a BMI of at least 27, against placebo | 68 weeks | WOMAC knee-pain score and percentage change in body weight | Completed. NEJM, online 8 Nov 2026 |
| TRIUMPH-5 · NCT06662383 | About 800 adults with obesity, against tirzepatide, an approved prescription medicine | 80 weeks | Percentage change in body weight | Active, not recruiting; primary completion expected Nov 2026 |
| TRIUMPH-6 · NCT06859268 | About 643 adults with obesity (phase 3b). After a period on retatrutide, participants stay on it, change strength or switch to placebo | 116 weeks | Percentage change in body weight from week 0 | Active, not recruiting; Apr 2028 |
| TRIUMPH-7 · NCT07035093 | About 586 adults with obesity or overweight and chronic low back pain, against placebo | Up to 72 weeks | Back-pain intensity on a numeric rating scale, and percentage change in body weight | Active, not recruiting; Sep 2027 |
| TRIUMPH-8 · NCT07232719 | About 250 adults with obesity or overweight, without type 2 diabetes, against placebo (phase 3b) | 56 weeks | Percentage change in body weight | Active, not recruiting; Jun 2027 |
| TRIUMPH-9 · NCT07357415 | About 600 adults with obesity or overweight, without type 2 diabetes (phase 3b). Three ways of starting treatment, compared with each other; no placebo group | 104 weeks | Percentage change in body weight | Active, not recruiting; Oct 2028 |
| TRIUMPH-Outcomes · NCT06383390 | About 10,000 adults aged 45 or older with a BMI of 27 or more and atherosclerotic cardiovascular disease, chronic kidney disease or both, against placebo | Event-driven, about 248 weeks | Time to a first major cardiovascular event; time to kidney failure, a sustained fall of 40% or more in kidney filtration (eGFR), or cardiovascular or kidney death | Active, not recruiting; Feb 2029 |
All ten are randomised and double-blind, and Eli Lilly sponsors all of them. Phase 3 unless marked 3b.
02What are the TRIUMPH trials?
TRIUMPH is the name Eli Lilly gives its phase 3 programme for retatrutide, an investigational drug that activates the GIP, GLP-1 and glucagon receptors, in adults with obesity or overweight. A 2025 design paper by Lilly staff and academic investigators describes the core of it: four registrational trials, meaning trials designed to support an application for approval. They are “four Phase 3, multicenter, randomized, double-blind studies” comparing retatrutide with placebo, alongside advice on diet and physical activity, in more than 5,800 participants. Lilly’s release of 29 September 2026 gives the same count and says the programme began in 2023.
Two of the four, TRIUMPH-1 and TRIUMPH-2, are basket trials. Smaller trials in knee osteoarthritis or obstructive sleep apnoea sit inside a main weight-management trial, and each is analysed on its own. TRIUMPH-3 enrols people with cardiovascular disease, and TRIUMPH-4 is a stand-alone knee osteoarthritis trial.
Beyond these four, ClinicalTrials.gov lists TRIUMPH-5 to TRIUMPH-9, and Lilly’s medical information service lists a heart and kidney outcomes trial as TRIUMPH-Outcomes. Lilly runs a separate phase 3 programme in type 2 diabetes, TRANSCEND-T2D; one of its trials, TRANSCEND-T2D-1, appeared in The Lancet in June 2026 and is not covered here. The drug itself: what is retatrutide?
03Who took part in the TRIUMPH trials?
Adults only: every registry record sets a minimum age of 18, and TRIUMPH-Outcomes sets 45. All have obesity or overweight. Each trial then narrows the group:
- Without type 2 diabetes: TRIUMPH-1, TRIUMPH-4, TRIUMPH-8 and TRIUMPH-9.
- With type 2 diabetes: TRIUMPH-2, which required an HbA1c of 6.5% to 10.5% on stable diabetes treatment.
- With cardiovascular or kidney disease: TRIUMPH-3 (cardiovascular disease) and TRIUMPH-Outcomes (cardiovascular disease, chronic kidney disease or both).
- With a painful joint or back: knee osteoarthritis in TRIUMPH-4 and TRIUMPH-1-OA; chronic low back pain in TRIUMPH-7.
- With moderate-to-severe obstructive sleep apnoea: TRIUMPH-1-OSA (243 people) and TRIUMPH-2-OSA (448).
The papers report who was actually randomised. In TRIUMPH-2, for example, the mean age was 55, the mean BMI was 38.2 and 48% of participants were women. TRIUMPH-1 to TRIUMPH-4 drew participants from North and South America, Europe, India and Australia, by their registry site lists.
04What did the TRIUMPH trials measure?
Every TRIUMPH weight trial has the same primary endpoint: the percentage change in body weight from the start of the trial, compared with placebo in most trials, with tirzepatide in TRIUMPH-5 and between ways of starting treatment in TRIUMPH-9. The other primary endpoints:
The pain subscale of WOMAC, a questionnaire on knee osteoarthritis, at week 68 (TRIUMPH-4) or week 80 (TRIUMPH-1-OA).
The apnoea–hypopnoea index, the average number of pauses and shallow breaths per hour of sleep, at week 80.
Pain intensity on a numeric rating scale, up to week 72 (TRIUMPH-7).
Time to a first major cardiovascular event, and time to a first major kidney event or cardiovascular or kidney death (TRIUMPH-Outcomes).
Two design details to know before reading the papers. First, the basket design splits the trial’s allowance for a false-positive finding (α = 0.05) between the main weight trial and each nested trial, so that each can be analysed on its own. Second, the papers report results under more than one estimand: a pre-specified rule for handling people who stop treatment or start another. The same trial can give different numbers depending on the rule, so compare like with like.
05What did the TRIUMPH papers report on safety?
Retatrutide is investigational and not approved anywhere, so we report the trials’ design and leave out their efficacy figures. Their adverse-event findings are part of the record, in the abstracts’ words and without dose labels.
- TRIUMPH-1: the most common adverse events were gastrointestinal.
- TRIUMPH-2: gastrointestinal events, low blood pressure and dysaesthesia (altered skin sensation) were more frequent than with placebo, and stopping treatment for good because of adverse events or death was more frequent in two of the three retatrutide groups.
- TRIUMPH-4 and TRIUMPH-1-OA: serious adverse events were more common with retatrutide than with placebo, and the most common adverse events were gastrointestinal.
- TRIUMPH-1-OSA and TRIUMPH-2-OSA: the most common adverse events were gastrointestinal.
These describe Lilly’s product under trial conditions, not material sold under the same name. How to read safety data like this: peptide side effects, documented and unknown.
06What are the limits of the TRIUMPH trials?
- Anything about products sold online. Every trial tested Lilly’s product, made and checked for the trials. In November 2026 Australia’s TGA found that tested products from one brand, sold as retatrutide, “contained less retatrutide than stated on the label, with significant variation between samples”. More: contamination and mislabeling.
- Long-term effects. The longest published trials ran 80 weeks. Heart and kidney outcomes await TRIUMPH-Outcomes, with primary completion expected in February 2029.
- How retatrutide compares with approved medicines. TRIUMPH-1 to TRIUMPH-4 used placebo. TRIUMPH-5, against tirzepatide, has not reported.
- TRIUMPH-3’s findings. It is completed, but we found no journal paper (PubMed, 18 Nov 2026), and ClinicalTrials.gov shows no posted results.
- Independent replication. Lilly funded every TRIUMPH trial, and Lilly staff are among the authors of each TRIUMPH paper we read. Outside TRIUMPH, a phase 2 trial of retatrutide by another sponsor, Hudson Biotech (NCT07467447), is recruiting, with no results posted (ClinicalTrials.gov, 18 Nov 2026).
- Results outside the trial setting. Participants were adults chosen by the trials’ criteria and given diet and activity advice alongside treatment. Children and adolescents were not enrolled.
- Full details. We read the abstracts and registry records; several full texts are paywalled.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.
07Where do the TRIUMPH trials fit in the evidence?
TRIUMPH is the late-stage step in a sequence that is still running:
- 2022: Lilly’s phase 1 studies are published, among them a 12-week phase 1b trial of 72 adults with type 2 diabetes, whose primary outcome was safety and tolerability.
- June 2023: a phase 2 obesity trial of 338 adults over 48 weeks appears in NEJM.
- May to August 2023: TRIUMPH-3, TRIUMPH-1, TRIUMPH-2 and TRIUMPH-4 begin, by their registry start dates.
- October 2025: the TRIUMPH design paper is published.
- September to November 2026: the TRIUMPH-1, TRIUMPH-2, sleep apnoea and knee osteoarthritis papers appear in NEJM and The Lancet.
- First quarter of 2027: Lilly says it “plans to submit a Biologics License Application (BLA)” to FDA. A submission asks FDA to review the evidence; it is not an approval.
On our scale these are T1 trials: randomised and controlled, of one company’s investigational product. What the grades mean: evidence grades.